Suppr超能文献

经皮凝血酶注射治疗内脏假性动脉瘤的效用。

Utility of percutaneous thrombin injection for treating visceral pseudoaneurysms.

机构信息

Department of Radiodiagnosis, PGIMER, Chandigarh, India.

出版信息

Minim Invasive Ther Allied Technol. 2021 Jun;30(3):174-178. doi: 10.1080/13645706.2020.1720251. Epub 2020 Jan 31.

Abstract

PURPOSE

To assess the efficacy and outcome of percutaneous thrombin injection in treatment of visceral arterial pseudoaneurysms (PAs) in a selective group of patients.

MATERIAL AND METHODS

Retrospective review of the institutional database showed 19 cases of visceral arterial pseudoaneurysms that were treated with percutaneous ultrasound-guided thrombin injection between January 2014 and December 2019 (13 men and 6 women). Of the pseudoaneurysms, 36% were due to pancreatitis, 35% were iatrogenic, 21% were infective and 8% traumatic. Most of the pseudoaneurysms arose from the hepatic artery (27%) followed by the splenic artery (26%) and renal artery (21%). Mean sac size of the pseudoaneurysms was 23 mm (range, 8 -40 mm). Technical success was defined as absence of flow within the PAs on follow-up ultrasonography (USG) 24 h and 3 days after thrombin injection.

RESULTS

Overall technical success was seen in 10/19 patients. Technical success of thrombin injection was higher in cases of distal branch PAs as compared to main vessel PAs (9/13 vs. 1/6). Success rates were higher with smaller (<23mm) pseudoaneurysms (7/12) as compared to larger ones (3/7). There were no procedure-related complications.

CONCLUSION

Ultrasound-guided percutaneous thrombin injection is a novel method of treating visceral pseudoaneurysms as a painless, cheap and radiation-free procedure. However, further large-scale studies are needed to prove the efficacy in treating visceral pseudoaneurysms.

摘要

目的

评估经皮超声引导下凝血酶注射治疗特定患者内脏动脉假性动脉瘤(PAs)的疗效和结果。

材料和方法

回顾性分析机构数据库显示,2014 年 1 月至 2019 年 12 月期间,19 例内脏动脉假性动脉瘤患者采用经皮超声引导下凝血酶注射治疗(13 例男性,6 例女性)。假性动脉瘤中,36%由胰腺炎引起,35%为医源性,21%为感染性,8%为创伤性。大多数假性动脉瘤起源于肝动脉(27%),其次是脾动脉(26%)和肾动脉(21%)。假性动脉瘤的平均囊腔大小为 23mm(范围,8-40mm)。技术成功定义为凝血酶注射后 24 小时和 3 天的随访超声(USG)未见 PAs 内血流。

结果

19 例患者中,10 例患者获得总体技术成功。与主血管 PAs 相比,远端分支 PAs 的凝血酶注射技术成功率更高(9/13 比 1/6)。与较大的假性动脉瘤(3/7)相比,较小的(<23mm)假性动脉瘤的成功率更高(7/12)。无与操作相关的并发症。

结论

超声引导下经皮凝血酶注射是一种治疗内脏假性动脉瘤的新方法,具有无痛、廉价和无辐射的优点。然而,需要进一步的大规模研究来证明其治疗内脏假性动脉瘤的疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验